Currently Viewing:
The American Journal of Managed Care June 2019
Reports of the Demise of Chemotherapy Have Been Greatly Exaggerated
Bruce Feinberg, DO; Jonathan Kish, PhD, MPH; Igoni Dokubo, MD; Jeff Wojtynek, PharmD; and Kevin Lord, PhD, MHS
From the Editorial Board: Patrick H. Conway, MD, MSc
Patrick H. Conway, MD, MSc
Association of Decision Support for Hospital Discharge Disposition With Outcomes
Winthrop F. Whitcomb, MD; Joseph E. Lucas, PhD; Rachel Tornheim, MBA; Jennifer L. Chiu, MPH; and Peter Hayward, PhD
US Care Pathways: Continued Focus on Oncology and Outstanding Challenges
Anita Chawla, PhD; Kimberly Westrich, MA; Angela Dai, BS, BA; Sarah Mantels, MA; and Robert W. Dubois, MD, PhD
Understanding Price Growth in the Market for Targeted Oncology Therapies
Jesse Sussell, PhD; Jacqueline Vanderpuye-Orgle, PhD; Diana Vania, MSc; Hans-Peter Goertz, MPH; and Darius Lakdawalla, PhD
Cancer Care Spending and Use by Site of Provider-Administered Chemotherapy in Medicare
Andrew Shooshtari, BS; Yamini Kalidindi, MHA; and Jeah Jung, PhD
Will 2019 Kick Off a New Era in Person-Centered Care?
Ann Hwang, MD; and Marc A. Cohen, PhD
Enhanced Care Coordination Improves HIV Viral Load Suppression Rates
Ross G. Hewitt, MD; Debra Williams, EdD; Richard Adule; Ira Feldman, MPS; and Moe Alsumidaie, MBA, MSF
Impact of Care Coordination Based on Insurance and Zip Code
Jennifer N. Goldstein, MD, MSc; Merwah Shinwari, BS; Paul Kolm, PhD; Daniel J. Elliott, MD, MSCE; William S. Weintraub, MD; and LeRoi S. Hicks, MD, MPH
Currently Reading
Changing Electronic Formats Is Associated With Changes in Number of Laboratory Tests Ordered
Gari Blumberg, MD; Eliezer Kitai, MD; Shlomo Vinker, MD; and Avivit Golan-Cohen, MD
Improving Quality Measure Maintenance: Navigating the Complexities of Evolving Evidence
Thomas B. Valuck, MD, JD; Sarah Sampsel, MPH; David M. Sloan, PhD; and Jennifer Van Meter, PharmD

Changing Electronic Formats Is Associated With Changes in Number of Laboratory Tests Ordered

Gari Blumberg, MD; Eliezer Kitai, MD; Shlomo Vinker, MD; and Avivit Golan-Cohen, MD
A slight decrease in the convenience of ordering a laboratory test led to a dramatic decrease in test utilization.
ABSTRACT

Objectives: To evaluate if changes in how laboratory test requests are presented in the electronic health record (EHR) would lead to less testing.

Study Design: Computerized laboratory data were used to compare the numbers of tests ordered before and after each change was introduced.

Methods: Leumit Health Services (a health maintenance organization [HMO] in Israel) has a central laboratory that serves HMO members in 340 clinics all over the country. We were able to compare the numbers of gamma glutamyl transferase (GGT) tests ordered during different periods of time during which the ways of presenting the parameters on the main laboratory screen of the EHR were changed.

Results: A dramatic reduction in orders occurred when GGT tests could be ordered only by the search engine function, instead of being ordered from 2 other lists that appear on the main screen—from about 36,000 to about 1000 per month. When the GGT test option was added back to just 1 place on the main screen, the numbers jumped back to 18,000, and when GGT returned to its original place in all the lists, back to more than 35,000. Since then, the GGT test is available on the main screen only in the batch of liver tests.

Conclusions: A slight decrease in the convenience of ordering a laboratory test that is not indicated for routine screening led to a dramatic decrease in the number of test orders sent. Convenience is a positive thing when it saves precious time, but if it leads to overtesting, we shall not have gained much.

Am J Manag Care. 2019;25(6):e179-e181
Takeaway Points

Preventing overdiagnosis is a major goal for healthcare providers. Although laboratory tests in the community are not necessarily expensive, they do add up and can cause overdiagnosis in the ambulatory setting. We found that a simple measure that reduced accessibility on the main screen of the electronic health record prevented physicians from routinely clicking to order gamma glutamyl transferase tests, and this led to a very significant reduction in the numbers of tests ordered. Such a measure is easily applicable to varied healthcare settings and can make a great difference in reducing related costs.
  • Overtesting is prevalent in primary care.
  • Avoiding this is feasible at the level of primary care.
  • Workable solutions can be very simple.
The use of gamma glutamyl transferase (GGT) levels as a screening test for liver function is controversial.1-3 Its main utility is in cases in which alkaline phosphatase is elevated, to differentiate between hepatobiliary or bone origin, but isoenzymes of alkaline phosphatase are more accurate in this case. It can also be used in patients with alcoholism to monitor alcohol intake and adherence to treatment regimens or to identify occult alcoholism. Many reasons exist for false-positive elevated GGT (it has very low specificity for liver disease), and in most cases, if the transaminases are not elevated, no serious liver problem is present. GGT is best used as a second-line laboratory test and not as a screening test. An isolated elevation of GGT does not need to be further evaluated unless the patient has additional clinical risk factors for liver disease.1

Electronic health records (EHRs) can both help and harm the quality of healthcare. The ability to choose tests by marking them off on a computerized list has positive implications in saving time for the busy primary care physician. One does not need to search for the specific test or remember how it is spelled. On the other hand, making the decision too easy is likely to lead to the ordering of more tests than are actually needed. If tests are marked off without enough thought being given to the choices (eg, when they are presented in prespecified batches), physicians are very likely to order tests that are not especially useful. Overtesting can lead to overdiagnosis and down the line may cause overtreatment.

In Israel, EHRs have been used in health maintenance organizations (HMOs) for more than 20 years. Requests for laboratory tests are also computerized. In the Leumit HMO, which has 340 clinics distributed across Israel, there are 3 ways to find and mark laboratory tests to be ordered. The EHR has a first screen, which pops up when the laboratory function is accessed. This screen shows categories of commonly used laboratory tests (eg, blood chemistry, endocrinology, serology, urine analysis) that can be chosen one by one. To make the task easier for busy physicians, there are also several groups that can be marked as a batch, such as liver tests, lipid profile tests, kidney function tests, and tests used for following up the use of atypical antipsychotics. It is possible to choose only some of the included tests in the group, but it is easier to mark the whole group. At the bottom of the screen is a search function, which allows the physician to find any laboratory test done in the HMO by usual search methods. Although the groups and checklist are intended to make the physician’s job easier (and they do), they also have the potential to lead to overtesting. When we analyze laboratory testing among groups of doctors, we find that too many physicians choose the whole group instead of clicking on each individual test as needed.

Some previous work has tackled this issue. In a study from Finland, blood tests considered to be of limited utility (erythrocyte sedimentation rate and aspartate transaminase) were made harder to find—by the researchers’ estimates, an extra 4 to 8 seconds of work was needed to write the orders by hand—causing a decrease of 90% in the tests’ ordering.4 In our HMO, a similar study was done when vitamin B12, folic acid, and ferritin—which are considered second-line tests for the work-up of anemia—were removed from the main screen and available only via the search feature. Decreases of 31% to 41% were seen in the first month; they decreased further after the second month.5

In the largest HMO in Israel, a group of experienced, academically affiliated family practitioners and pediatricians took part in a pilot study.6 Liver tests were divided into 3 groups to be chosen as would fit a particular patient’s situation: screening, further work-up, or full evaluation. Only the last included GGT. The pilot group showed a significant decrease in tests ordered—17%—versus an increase of 8.6% over the whole district.

This was a descriptive study in which we utilized a change in test presentation to observe the implications on numbers of tests. When some changes were made on the main laboratory screen that changed the accessibility of GGT testing over several months, we took the opportunity to analyze and describe what implications this would have on the numbers of tests ordered of this liver enzyme. We hypothesized that when physicians had access to the convenience of checking off GGT on the main screen, larger numbers would order the test, compared with decreased numbers when they would, less conveniently, have to search specifically for it.

METHODS

This was a descriptive study done in the Leumit HMO. Leumit has a central laboratory that serves the entire HMO all over Israel, serving 340 branches in varied populations. We were able to compare the numbers of GGT tests ordered at different times during which the parameters were changed on the main laboratory screen of the EHR. Historically, GGT appeared in the “liver tests” on the main screen and also in the “general chemistry tests” as one of a long list, as well as via the search engine for laboratory test requests.

In April 2014, the laboratory decided to remove GGT from the main laboratory screen so that it could only be ordered if searched for specifically. When we realized this, we undertook this study to see if behaviors would change as a result and gathered data. After 2 months, GGT was returned, at first partially, then completely to the original status, which enabled us to see the greater picture. At that point (June 2015), the laboratory decided to leave GGT as part of the liver tests batch but to remove it from the list under general chemistry tests. This is the situation today.


 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up